Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754373 | 0.90 | SIGMAR1 (0.60) | SIGMAR1KMT2ADRD2DRD4LMNA | |
| SCHEMBL7683649 | 0.88 | ACHE (0.54) | DRD2DRD4ACHE | |
| Hydrochloric Acid SCHEMBL7684460 | 0.87 | ACHE (0.53) | DRD2DRD4ACHE | |
| SCHEMBL7684678 | 0.81 | ALDH1A1 (0.47) | KMT2ALMNASMN1; SMN2KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7688079 | 0.80 | MEN1 (0.46) | KMT2ALMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL14052246 | 0.76 | KMT2A (0.55) | SIGMAR1KMT2ADRD2DRD4LMNA | |
| Hydrochloric Acid SCHEMBL7777094 | 0.76 | SIGMAR1 (0.60) | SIGMAR1KMT2ADRD2DRD4LMNA | |
| SCHEMBL7679658 | 0.75 | ACHE (0.60) | KMT2AACHEBACE1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL7777090 | 0.74 | SIGMAR1 (0.58) | SIGMAR1KMT2ADRD2DRD4LMNA | |
| SCHEMBL6857224 | 0.74 | SIGMAR1 (0.60) | SIGMAR1KMT2ADRD2DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072905-A1 | Novel process for preparing dopenzil and its derivatives | TIAN JIN HEMAY BIO-TECH CO., LTD (CN) | 2007-03-29 | — | — | US | disclosed |
| US-6492522-B1 | OPTICAL ISOMERS AND SALTS WITH 4-PYRIDINECARBOXALDEHYDE IN THE PRESENCE OF BASE TO GIVE A COMPOUND OF THE FORMULA REACTING THE COMPOUND OBTAINED IN STEP B) ABOVE OR A SALT THEREOF WITH A COMPOUND OF FORMULA R.SUP.10 X, WHEREIN R.SUP.10, | FINETECH LABORATORIES LTD. (IL) | 2002-12-10 | — | — | US | disclosed |
| EP-1129073-A2 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF DONEPEZIL AND RELATED COMPOUNDS | Finetech Ltd (IL) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000009483-A2 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF DONEPEZIL AND RELATED COMPOUNDS | FINETECH LTD. (IL) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072905-A1 | Novel process for preparing dopenzil and its derivatives | HRH4, HRH3, HRH1 | SIGMAR1 85/4885KMT2A 748/4885DRD2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.